Puma Biotechnology Inc

PBYI

$5.86

Name : Puma Biotechnology Inc

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $295,291,904.00

EPSttm : 0.74

Puma Biotechnology Inc

$5.86

1.35%

$0.08

Float Short %

8.98

Margin Of Safety %

Put/Call OI Ratio

0.05

EPS Next Q Diff

-0.13

EPS Last/This Y

-0.09

EPS This/Next Y

-0.14

Price

5.86

Target Price

3.5

Analyst Recom

Performance Q

16.5

Relative Volume

0.77

Beta

1.21

Ticker: PBYI

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-08	PBYI	5.39	0.03	0.02	4808
2025-12-09	PBYI	5.53	0.03	0.00	4883
2025-12-10	PBYI	5.59	0.03	0.00	4947
2025-12-11	PBYI	5.72	0.03	0.00	5000
2025-12-12	PBYI	5.86	0.02	0.03	5198
2025-12-15	PBYI	5.83	0.02	0.74	5267
2025-12-16	PBYI	5.66	0.03	1.23	5301
2025-12-17	PBYI	5.57	0.04	999.99	5355
2025-12-18	PBYI	5.62	0.04	999.99	5356
2025-12-19	PBYI	5.7	0.04	0.06	5366
2025-12-22	PBYI	5.81	0.05	0.14	2326
2025-12-23	PBYI	5.92	0.05	0.00	2341
2025-12-26	PBYI	6.16	0.05	0.00	2403
2025-12-29	PBYI	6.1	0.05	0.00	2418
2025-12-30	PBYI	6.01	0.05	0.24	2425
2025-12-31	PBYI	5.95	0.05	999.99	2446
2026-01-02	PBYI	5.78	0.05	0.00	2450
2026-01-05	PBYI	5.95	0.05	0.00	2470
2026-01-06	PBYI	5.86	0.05	0.00	2520
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-08	PBYI	5.40	-46.5	-	0.69
2025-12-09	PBYI	5.52	-46.5	-	0.69
2025-12-10	PBYI	5.59	-46.5	-	0.69
2025-12-11	PBYI	5.72	-46.5	-	0.69
2025-12-12	PBYI	5.86	-46.5	-	0.69
2025-12-15	PBYI	5.82	-46.5	-	0.69
2025-12-16	PBYI	5.82	-46.5	-	0.69
2025-12-17	PBYI	5.58	-46.5	-	0.69
2025-12-18	PBYI	5.63	-46.5	-	0.69
2025-12-19	PBYI	5.65	-46.5	-	0.69
2025-12-22	PBYI	5.87	-46.5	-	0.69
2025-12-23	PBYI	5.95	-46.5	-	0.69
2025-12-26	PBYI	6.17	-46.5	-	0.69
2025-12-29	PBYI	6.09	-46.5	-	0.69
2025-12-30	PBYI	6.00	-46.5	-	0.69
2025-12-31	PBYI	5.95	-46.5	-	0.69
2026-01-02	PBYI	5.78	-46.5	-	0.69
2026-01-05	PBYI	5.95	-46.5	-	0.69
2026-01-06	PBYI	5.86	-46.5	-	0.69
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-08	PBYI	-1.64	4.02	8.73
2025-12-09	PBYI	-1.64	4.02	8.73
2025-12-10	PBYI	-1.64	4.02	8.93
2025-12-11	PBYI	-1.64	4.02	8.93
2025-12-12	PBYI	-1.64	4.02	8.93
2025-12-15	PBYI	-1.64	4.04	8.93
2025-12-16	PBYI	-1.64	4.04	8.93
2025-12-17	PBYI	-1.64	4.04	8.93
2025-12-18	PBYI	-0.91	4.04	8.93
2025-12-19	PBYI	-0.91	4.04	8.93
2025-12-22	PBYI	-0.91	4.04	8.93
2025-12-23	PBYI	-0.91	4.04	8.93
2025-12-26	PBYI	-0.91	4.04	8.98
2025-12-29	PBYI	-0.91	4.04	8.98
2025-12-30	PBYI	-0.91	4.04	8.98
2025-12-31	PBYI	-0.91	4.04	8.98
2026-01-02	PBYI	-0.91	4.04	8.98
2026-01-05	PBYI	-0.91	4.04	8.98
2026-01-06	PBYI	-0.91	4.04	8.98
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.17

Avg. EPS Est. Current Quarter

0.23

Avg. EPS Est. Next Quarter

0.04

Insider Transactions

-0.91

Institutional Transactions

4.04

Beta

1.21

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

7.48

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

58.5

Max Drawdown 5-Year %

-88

Target Price

3.5

P/E

7.91

Forward P/E

13.04

PEG

P/S

1.39

P/B

2.56

P/Free Cash Flow

6.89

EPS

0.74

Average EPS Est. Cur. Y

0.69

EPS Next Y. (Est.)

0.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

17.44

Relative Volume

0.77

Return on Equity vs Sector %

Return on Equity vs Industry %

20.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Puma Biotechnology Inc

Sector: Healthcare

Industry: Biotechnology

Employees: 172

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

stock quote shares PBYI – Puma Biotechnology, Inc. Stock Price stock today

news today PBYI – Puma Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch PBYI – Puma Biotechnology, Inc. yahoo finance google finance

stock history PBYI – Puma Biotechnology, Inc. invest stock market

stock prices PBYI premarket after hours

ticker PBYI fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PBYI

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y